
Genomics beyond drug selection: Using DNA and RNA data
This workshop is designed for oncologists, pathologists, oncology nurses and other medical professionals involved in patient care for cancer patients. Saturday, September 23 · 7am – 5pm CDT
This workshop is designed for oncologists, pathologists, oncology nurses and other medical professionals involved in patient care for cancer patients. Saturday, September 23 · 7am – 5pm CDT
Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with Artificial Intelligence Irvine, California– April
Combining Longitudinal Real-World Data and Clinical Genomics Data Will Enable a More Precise Approach to Cancer Care and Research NEW YORK – COTA, Inc., an
GTC was recently published in the Journal of Medical Artificial Intelligence – Accuracy of predicting IgHV mutation status in chronic lymphocytic leukemia using RNA expression profiling and machine learning.
ASH is just over a month away. Come meet with the GTC team and its co-op partners at our happy hour event. Download your invitation
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative
SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as
Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap